Tıkayıcı uyku apnesi sendromunda farmakoterapiler

Tıkayıcı uyku apnesi (TUA), sık karşılaşılan, özellikle kardiyovasküler sistem üzerindeki etkileri ile ciddi morbiditeye neden olan bir hastalıktır. CPAP (Continuous Positive Airway Pressure) oldukça etkili bir tedavi seçeneği olmasına rağmen, hastaların pek çoğu alternatif yöntemler aramaktadırlar. TUA tedavisinde pek çok ilaç üzerinde çalışmalar yapılmıştır. Bu ilaçların pek çoğu etkisiz bulunmuş ya da istenmeyen yan etkiler yaratmışlardır. TUA'nın patofizyolojisinin daha iyi anlaşılması ile ilaç tedavisinin belirli hastalarda fayda sağlayabileceği düşünülmektedir. Bu derlemede TUA tedavisinde etkili olabileceği düşünülen ilaçlar tartışılmaktadır.

Pharmacotherapies in obstructive sleep apnea

Obstructive sleep apnea (OSA) is a common disorder, causing considerable morbidity particularly because of its effects on cardiovascular system. Continuous positive airway pressure (CPAP) is extremely effective in the majority of patients but most patients would prefer an alternative. Various drugs have been investigated for the treatment of OSA. Most of the drugs have been found to be ineffective or have produced intolerable adverse effects. It seems likely that by better understanding the pathophysiology of OSA in individual patients, drug therapy might be beneficial in a certain group of patients.

Kaynakça

1) Diagnostic Classification Steering Committee, Thorpy MJ. International classification of sleep disorders: diagnostic and coding manual. Rochester (MM): American Sleep Disorders Association, 1990.

2) Smith IE, Quinnell TG. Pharmacotherapies for obstructive sleep apnoea: where are we now? Drugs. 2004;64(13):1385-99. [ Özet ]

3) Davies RJ, All NJ, Stradling JR. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax 1992; 47: 101-5. [ Özet ]

4) Flemons WW, Whitelaw WA, Brant R, et al. Likelihood ratios for a sleep apnoea clinical prediction rule. Am J Respir Crit Care Med 1994; 150: 1279-85. [ Özet ]

5) Ayappa I, Rapoport DM. The upper airway in sleep: physiology of the pharynx. Sleep Med Rev. 2003;7:9-33 [ Özet ]

6) Younes M, Ostrowski M, Thompson W, et al. Chemical control stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163: 829-39. [ Özet ]

7) Friberg D. Heavy snorers\' disease: a progressive local neuropathy. Acta Otolaryngol 1999; 119: 925-33. [ Özet ]

8) Issa FG, Sullivan CE. Alcohol, snoring and sleep apnea. J Neural Neurosurg Psychiatry 1982; 45: 353-9. [ Özet ]

9) Young T, Palta M, Dempsey J, et al. The occurrence of sleep disordered breathing in middle aged adults. N Engl I Med 1993; 328: 1230-5. [ Özet ]

10) Stradling JR, Barbour C, Gleimon J, et al. Prevalence of sleepiness and its relation to autonomic arousal and increased inspiratory effort in a community based population of men and women. J Sleep Res 2000; 9: 381-8. [ Özet ]

11) Olson LG, King MT, Hensley MJ, et al. A community study of snoring and sleep disordered breathing prevalence. Am J Respir Crit Care Med 1995; 152: 711-6. [ Özet ]

12) Bixler E, Vgontzas A, Ten Have T, et al. Prevalence of sleep disordered breathing in women. Am J Respir Crit Care Med 2001; 163:608-13. [ Özet ]

13) Lacasse Y, Godbout C, Series F. Health-related quality of life in obstructive sleep apnoea. Eur Respir J 2002; 19: 499-503. [ Özet ]

14) Shahar E, Whitney CW, Redline S, et al. Sleep disordered breathing and cardiovascular disease. Am J Respir Crit Care Med 2001; 163: 19-25. [ Özet ]

15) Nieto FJ, Young TB, Lind BK, et al. Association of sleep disordered breathing, sleep apnea and hypertension in a large community based study: Sleep Heart Health Study. JAMA 2000; 283: 1829-36. [ Özet ]

16) Lavie P, Heret P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-82. [ Özet ]

17) Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. [ Özet ]

18) Cistuli P, Barnes D, Grunstein R, et al. Effect of short term hormone replacement in the treatment of obstructive sleep apnoea in post-menopausal women. Thorax 1994; 49: 699-702. [ Özet ]

19) Block AJ, Wynne JW, Boysen PG, et al. Menopause, medroxyprogesterone and breathing during sleep. Am J Med 1981; 70: 506-10. [ Özet ]

20) Cook WR, Benich JJ, Woolen SA. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989; 96: 262-6. [ Özet ]

21) Yee B, Liu PY, Yang Q, et al. A double blind, placebo controlled randomised crossover study of intramuscular testosterone esters on sleep in men over 60 years of age. J Sleep Res 2002; 11 Suppl. 1: 254. [ Özet ]

22) Sandblom RE, Matsumoto AM, Schoene RB, et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983; 308: 508-10. [ Özet ]

23) Stewart DA, Grunstein RR, Berthon-Jones M, et al. Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea. Am Rev Respir Dis 1992; 146:1389-1393. [ Özet ]

24) Luboshitzky R, Aviv A, Hefetz A et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002; 87: 3394-8. [ Özet ]

25) White DP, Zwillich CW, Pickett CK, et al. Central sleep apnoea: improvement with acetazolamide therapy. Arch Intern Med 1982; 142: 1816-9. [ Özet ]

26) Tojima H, Kunitomo F, Kimura H, et al. Effects of acetazolamide in patients with sleep apnoea syndrome. Thorax 1988; 43: 113-9. [ Özet ]

27) Whyte K, Gould G, AMie A, et al. Role of protriptyline and acetazolamide in the sleep apnoea/hypopnoea syndrome. Sleep 1988; 11:463-72. [ Özet ]

28) Javaheri S, Evers JAM, Teppema LJ. Increase in ventilation caused by aminophylline in the absence of changes in ventral medullary extra cellular fluids, pH and carbon dioxide tension. Thorax 1989; 44: 121-5. [ Özet ]

29) Aubier M, Detroya A, Sampson M, et al. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305: 249-52. [ Özet ]

30) Mulloy E, Mc Nicholas WT. Theophylline in obstructive sleep apnoea: a double blind evaluation. Chest 1992; 101: 753-7. [ Özet ]

31) Espinosa H, Antic R, Thornton AT, et al. The effects of aminophylline on the sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1987; 136: 80-4. [ Özet ]

32) Saletu B, Oberndorfer S, Anderer P, et al. Efficiency of continuous positive airway pressure versus theophyllme therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology 1999; 39: 151-9. [ Özet ]

33) Gislason T, Almqvist M, BomanG, et al. Increased CSF opioid activity in sleep apnea syndrome: regression after successful treatment. Chest 1989; 96: 250-4. [ Özet ]

34) Atkinson RL, Suratt PM, Wilhoit SC, et al. Naloxone improves sleep apnea in obese humans. Int J Obes Relat Metab Disord 1985; 9: 233-9. [ Özet ]

35) Suratt PM, Wilhoit SC, Brown ED, et al. Effect of doxapram on obstructive sleep apnea. Bull Eur Physiopathol Respir 1986; 22: 127-31. [ Özet ]

36) Shao XM, Feldman JL. Pharmacology of nicotinic receptors in preBotzinger complex that mediate modulation of respiratory pattern. J Neurophysiol 2002; 88: 1851-8. [ Özet ]

37) Gothe B, Strohl KP, Levin S, et al. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest 1985; 87: 11-7. [ Özet ]

38) Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994; 150:469-74. [ Özet ]

39) Keating GM, Raffin MJ. Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs. 2005;19:785-803 [ Özet ]

40) Weichler U, Herres-Mayer B, Mayer J, et al. Influence of antihypertensive drug therapy on sleep pattern and sleep apnea activity. Cardiology 1991; 78: 124-30. [ Özet ]

41) Mayer J, Peter JH. First experience with cilazapril in the treatment of sleep apnoea-related hypertension. Drugs 1991; 41 Suppl. 1: 37-47. [ Özet ]

42) Grote L, Wutkewicz K, Knaack L, et al. Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity. Am J Hypertens 2000; 13: 1280-7. [ Özet ]

43) Kraiczi H, Hedner J, Peker Y, et al. Comparison of atenolol, amlodipine, cnalapril. hydrochlorothiazide and losartan for antihypertensive treatment in obstructive sleep apnea. Am J Respir Crit Care Med 2000; 161: 1423-8. [ Özet ]

44) Planes C, Foucher A, Leroy M, et al. Effect of celiprolol treatment in hypertensive patients with sleep apnea. Sleep 1999; 22: 507-13. [ Özet ]

45) Kanno O, Clarenbach P. Effect of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalogr Clin Neurophysiol. 1985;60:478-84. [ Özet ]

46) Issa F. Effect of clonidine in obstructive sleep apnoea. Am Rev Respir Dis 1992; 145: 465-9. [ Özet ]

47) Smith PL, Haponik EF, Allen RP, et al. Bleecker ER. The effects of protriptyline in sleep-disordered breathing. Am Rev Respir Dis 1983;127:8-13. [ Özet ]

48) Hudgel DW. Pharmacologic treatment of obstructive sleep apnea. J Lab Clin Med 1995; 126: 13-8. [ Özet ]

49) Bonora M, St John WM, Bledsoe TA. Differential elevation by protriptyline and depression by diazepam of upper airway respiratory motor activity. Am Rev Respir Dis 1985; 131:41-5. [ Özet ]

50) Kubin L, Tojima H, Davies RO, et al. Serotonergic excitatory drive to hypoglossal motorneurons in the decerabrate cat. Neurosci Lett 1992; 139: 243-8. [ Özet ]

51) Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992; 72: 165-229. [ Özet ]

52) Jelev A, Sood S, Liu H, et al. Microdialysis perfusion of 5-HT into the hypoglossal motor nucleus differentially modulates genioglossus activity across natural sleep-wake states in rats. J Physiol (Lond) 2001; 532: 467-81. [ Özet ]

53) Morin D, Monteau R, Hilaire G. Compared effects of serotonin on cervical and hypoglossal activities: an in-vitro study in the newborn rat. J Physiol (Lond) 1992; 451: 605-29. [ Özet ]

54) Stradling J, Smith D, Radulovacki M, et al. Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J Sleep Res 2003; 12: 169-70. [ Özet ]

55) Sunderram J, Parisi RA, Strobel RJ. Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162:925-9. [ Özet ]

56) Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991; 100: 416-21. [ Özet ]

57) Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999; 22: 61-7. [ Özet ]

58) Sampol G, Munoz X, Sagales MT, et al. Long-term efficacy of dietary weight loss in sleep apnoea/hypopnoea syndrome. Eur Respir J 1998; 12: 1156-9. [ Özet ]

59) Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnea in hypothyroidism. Ann Intern Med 1984; 101: 491-4. [ Özet ]

60) Kapur VK, Koepsell TD, de Maine J, et al. Association of hypothyroidism and obstructive sleep apnea. Am J Respir Crit Care Med 1998; 158: 1379-83. [ Özet ]

61) Lin CC, Tsan KW, Chen PJ. The relationship between sleep apnea syndrome and hypothyroidism. Chest 1992; 102: 1663-7. [ Özet ]

62) Skatrud J, Iber C, Ewart R, et al. Disordered breathing during sleep in hypothyroidism. Am Rev Respir Dis 1981; 124:325-9. [ Özet ]

63) Mezon BJ, West P, MaClean JP, et al. Sleep apnea in acromegaly. Am J Med 1980; 69: 615-8. [ Özet ]

64) Hart TB, Radow SK, Blackard WG, et al. Sleep apnoea in active acromegaly. Arch Intern Med 1985; 145: 865-6. [ Özet ]

65) Perks WH, Horrocks PM, Cooper RA, et al. Sleep apnoea in acromegaly. BMJ 1980; 280: 894-7. [ Özet ]

Kaynak Göster